Latest Breaking News On - Flow cell - Page 1 : comparemela.com

Nautilus Biotechnology, Inc (NASDAQ:NAUT) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

South koreaPusan gwangyoksiSubra sankarCarrie mendivilBernd wollscheidDaniel brennanSujal patelYuko okuMartin huberParag mallickAnna mowryBirgit schillingBuck institute for research onCustomer service jobsWorld congressMorgan stanley

Nautilus Biotechnology Appoints Martin Huber, Ph D , as Vice President of Biochemistry and Flow Cell Development

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteomeSEATTLE, Nov. 01, 2023 .

Martin huberSubra sankarNautilus biotechnology incProduct development at nautilusUniversity of viennaFlow cell developmentFormer quantaporeVice presidentFlow cellIon torrentSenior vice presidentProduct developmentNautilus biotechnologySan francisco bay areaRegistration statementAnnual report

Nautilus Biotechnology Inc : Nautilus Biotechnology Appoints Martin Huber, Ph D , as Vice President of Biochemistry and Flow Cell Development

Nautilus Biotechnology Inc : Nautilus Biotechnology Appoints Martin Huber, Ph D , as Vice President of Biochemistry and Flow Cell Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Martin huberSubra sankarFlow cell developmentUniversity of viennaProduct development at nautilusNautilus biotechnology incVice presidentFlow cellIon torrentSenior vice presidentProduct developmentNautilus biotechnologySan francisco bay areaRegistration statementAnnual reportIhre watchlist

Nautilus Biotechnology Appoints Martin Huber, Ph D , as

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively.

Martin huberSubra sankarProduct development at nautilusNautilus biotechnology incFlow cell developmentUniversity of viennaVice presidentFlow cellIon torrentSenior vice presidentProduct developmentNautilus biotechnologySan francisco bay areaRegistration statementAnnual reportNasdaq naut

MGI Partners with National Cancer Centre Singapore

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

United statesAsia pacificJason chanTech singapore pte ltdNational cancer centre singaporeTech co ltdLab initiativeResearch useSingapore pteRoy tanGeneral managerCancer discovery hubFlow cellLife sciencePrecision medicine